roboscreen

What roboscreen does

Roboscreen GmbH is a Leipzig-based diagnostic company founded in 2000 that develops and commercializes in vitro diagnostic (IVD) and research-use-only (RUO) assays for viral hepatitis and neurodegenerative disease biomarkers. The company operates independently following a June 2020 management buyout from the Analytik Jena AG group, where it had been housed since 2005. Its portfolio spans three main product families: (1) RoboGene real-time PCR quantification kits for HBV DNA, HCV RNA, and HDV RNA, several carrying CE-IVD certification and one (HBV DNA Quantification Kit 3.1) certified under the EU IVDR regulation; (2) the INSTANT family of manual and CyBio FeliX-automated nucleic acid extraction kits; and (3) a neurodegeneration line comprising ELISAs for tau, alpha-synuclein, TDP43, prion protein, and the proprietary Neuro IP Kit and BD Tau Workflow for blood-based Alzheimer's biomarker enrichment. Supporting offerings include monoclonal antibodies, recombinant proteins, veterinary BSE/Scrapie rapid tests, and resold rPeptide research reagents.

Name

roboscreen

Legal name

Roboscreen GmbH

Website

https://roboscreen.com

Company type

Private

Founded year

2000

Operating status

Operating

Short description

Roboscreen GmbH is a Leipzig-based diagnostics company developing CE-IVD and IVDR-certified real-time PCR kits, nucleic acid extraction systems, and ELISA/antibody reagents for viral hepatitis (HBV, HCV, HDV) and neurodegenerative disease biomarker research, serving diagnostic laboratories, academic researchers, and veterinary labs worldwide.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry) (HLAMADAJ)

Keywords

• In vitro diagnostics
• Real-time PCR assays
• Hepatitis diagnostics
• Neurodegenerative biomarkers
• Nucleic acid extraction

Headquarters

HQ city

Leipzig

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. IVD Diagnostic Kits: Sale of CE-IVD and IVDR certified diagnostic kits for viral pathogens (HBV, HCV, HDV) and neurodegenerative disease markers. Includes manual and automated extraction kits combined with real-time PCR or ELISA detection.
2. Research Use Only (RUO) Products: Sale of RUO labeled products for research applications including ELISAs, antibodies, proteins, and extraction kits for academic and biotech research institutions.
3. Veterinary Diagnostic Products: EU approved rapid BSE and Scrapie tests for veterinary diagnostics in animals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Roboscreen develops, manufactures, and distributes in vitro diagnostic (IVD) and research-use-only (RUO) kits for clinical diagnostic laboratories and academic research institutions. Its core portfolio includes CE-IVD/IVDR-certified real-time PCR quantification kits for hepatitis B, C, and D viruses, nucleic acid extraction kits (INSTANT family), and a neurodegeneration line of ELISAs, immunoprecipitation kits (Neuro IP Kit, BD Tau Workflow), antibodies, and recombinant proteins for Alzheimer's, Parkinson's, and Creutzfeldt-Jakob disease research. The company also supplies EU-approved veterinary prion (BSE, Scrapie) diagnostic tests.

Product overview

Roboscreen GmbH offers a diversified diagnostic product portfolio comprising three main product families: (1) RoboGene real-time PCR-based viral pathogen quantification kits (HBV DNA, HCV RNA, HDV RNA) for hepatitis diagnostics; (2) INSTANT family of manual and automated nucleic acid extraction kits; and (3) neurodegeneration product line including ELISAs (TAU total/phosphorylated/non-p/aggregate, alpha-Synuclein total/pathological, TDP43 total, BetaPrion), the Neuro IP Kit for plasma biomarker enrichment, and BD Tau Workflows for brain-derived Tau detection. The portfolio further includes monoclonal and polyclonal antibodies, recombinant proteins, veterinary prion diagnostics (BetaPrion BSE and Scrapie EIA kits), and resold rPeptide products (Tau, Synuclein, Beta-Amyloid peptides and proteins). Products carry CE-IVD, IVDR, RUO, or EU-approved regulatory statuses. Founded in 2000 and operating independently since a 2020 management buyout from Analytik Jena AG, Roboscreen positions itself as a provider of high-quality diagnostic solutions for diagnostic laboratories worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• RoboGene HBV DNA Quantification Kit 3.1 IVDR-certified real-time PCR kit for clinical quantification of HBV DNA (genotypes A-H) in human EDTA-plasma samples, intended for clinical diagnostic laboratories.
• RoboGene HBV DNA Quantification Kit 3.0 CE-IVD real-time PCR kit for quantification of Hepatitis B Virus (HBV) DNA in human EDTA- or citrate plasma and serum samples, available in manual and automated versions.
• RoboGene HCV RNA Quantification Kit 3.0 CE-IVD real-time PCR kit for quantification of Hepatitis C Virus (HCV) RNA in human EDTA- or citrate plasma and serum samples, validated on multiple real-time PCR platforms.
• RoboGene HDV RNA Quantification Kit 2.0 CE-IVD real-time PCR kit for quantification of Hepatitis D Virus (HDV) RNA in human EDTA plasma or serum samples, intended for clinical management of patients with chronic HDV infections.
• RoboGene HDV RNA Quantification Kit 3.0 - RUO Research use only real-time PCR kit for quantification and detection of Hepatitis D Virus (HDV) RNA in plasma and serum samples, with improved sensitivity and support for genotypes 1-8.
• INSTANT Virus RNA/DNA Kit
• INSTANT Virus RNA/DNA Kit - FX CE-IVD automated magnetic bead-based extraction kit configured for use with the CyBio FeliX Basic Unit, supporting sample volumes of 200, 400, or 800 µl.
• Rapid INSTANT Virus RNA/DNA Kit - FX CE-IVD automated magnetic bead-based extraction kit optimized for minimal processing time, achieving up to 96 samples per run in approximately 35 minutes on the CyBio FeliX.
• INSTANT Virus RNA/DNA Kit - FX 2.0 Research use only automated extraction kit using magnetic particle binding technology, optimized for rapid preparation of highly pure viral RNA and DNA from cell-free biological samples.
• BD Tau Workflow Research workflow combining immunoprecipitation and luminescence-based ELISA for specific detection of brain-derived Tau in blood-based samples, co-developed with IBL/Tecan for Alzheimer's disease research.
• Neuro IP Kit Pre-analytical enrichment kit for Alzheimer's disease biomarkers from plasma using immunoprecipitation, enabling improved detection in downstream immunoassays.
• hSYN total ELISA Research use only sandwich ELISA for quantitative determination of alpha-Synuclein in human cerebrospinal fluid using an overnight protocol requiring 25 µl CSF.
• Human alpha-Synuclein PATHO ELISA Research use only sandwich ELISA for quantitative determination of beta-sheet oligomers of human alpha-Synuclein in biological samples, using mAb 5G4 for capturing.
• hTDP43 total ELISA Research use only sandwich ELISA for quantitative determination of human TDP43 protein in biological samples using mAb 21B2 for capture.
• Human TAU AGGREGATE ELISA Research use only sandwich ELISA for quantitative determination of human TAU aggregates in human and animal tissue samples and cell cultures without pre-treatment.
• BetaPrion HUMAN ELISA Research use only sandwich ELISA for quantitative determination of human prion protein total content in human cerebrospinal fluid, plasma, and serum.
• BetaPrion BSE EIA Test Kit EU approved rapid test for Bovine Spongiform Encephalopathy (BSE) testing on cattle in accordance with Regulation (EC) No 999/2001, with documented 100% sensitivity in 400 BSE positive samples and 100% specificity in 10,000+ negative samples.
• BetaPrion SCRAPIE EIA ELISA Research use only rapid test for SCRAPIE in sheep and goats, with one kit containing sufficient reagents for 90 ovine brain samples analysis.
• Tau & Beta-Amyloid Antibodies Monoclonal and polyclonal antibodies against isoforms of Tau protein, phosphorylated and double-phosphorylated Tau protein, and beta-Amyloid for neurodegenerative disease research.
• Alpha-Synuclein Antibodies Monoclonal and polyclonal antibodies targeting different sites of alpha-Synuclein, including the pathological beta-sheet form, for Parkinson's and related synucleinopathies research.
• TDP43 Antibodies Monoclonal antibodies directed to different epitopes of N-terminal, C-terminal, and central regions of TDP43, including phospho-specific antibodies for Ser409/410.
• NfL Antibodies Monoclonal antibodies against Neurofilament Light Chain (NfL), a biomarker of neuroaxonal injury elevated in Alzheimer's, Parkinson's, multiple sclerosis, and ALS.
• Prion Protein Antibodies Monoclonal and polyclonal antibodies to different binding sites of bovine and human prion protein for Creutzfeldt-Jakob disease research.
• Disease Related Antibodies Monoclonal antibodies to enzymes involved in inflammation processes related to neurological changes, including Calpain, Tissue transglutaminase (TTG), and Cyclooxygenase (COX) 1 and 2.
• Recombinant Proteins Recombinant proteins including human and animal prion proteins, alpha-Synuclein, and mutant P301L Tau-441 expressed in E. coli or insect cells for neurodegenerative disease research.
• rPeptide Tau Products Resold rPeptide products including recombinant human Tau proteins (isoforms 441, 410, 412, 381, 383, 352), mutant forms (P301L, R406W, V337M, G272V), and labeled variants.
• rPeptide Synuclein Products Resold rPeptide products including recombinant human, native and mutant Alpha-Synuclein (A53T, A30P, E46K, S9C), Beta-Synuclein, Gamma-Synuclein, and labeled variants.
• rPeptide Beta-Amyloid Products Resold rPeptide synthetic and labeled beta-amyloid peptides including fragments, precursor proteins, and monoclonal antibodies to beta-amyloid for Alzheimer's research.
• rPeptide Native Beta-Amyloid Peptides Resold rPeptide native human and mutant beta-amyloid peptides expressed in E. coli including 1-40, 1-42, 1-43, and 1-46 variants in various preparations.
• rPeptide Apolipoprotein E Resold rPeptide recombinant human plasma Apolipoprotein E expressed in E. coli.
• rPeptide AD/PD Related Proteins Resold rPeptide products including Alpha 1 Antichymotrypsin, Haptoglobin, Myeloperoxidase, and preformed fibrils of Alpha-Synuclein, Beta-Amyloid, and Tau for neurodegeneration research.
• HANTA Virus Antibodies Monoclonal antibodies to HANTA Virus proteins including Puumala and Dobrava strains, for research use.
• Detection Antibodies Monoclonal detection antibodies to DIG and FITC labeled proteins and PCR products for ELISA and Western blot applications.

Quantifiable outcome

• BD Tau workflow achieves Limit of Detection of 0.69 IU/ml with manual purification for HDV RNA quantification
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration23 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• IBL International / TecancoreStrategic or Co-development PartnerCollaboration to develop and launch the BD Tau Workflow for specific and sensitive measurement of brain-derived Tau in blood-based samples. Combines Roboscreen's immunoprecipitation expertise with Tecan's luminescence detection technology for Alzheimer's disease biomarker research.
• Fraunhofer IZIcoreStrategic or Co-development PartnerTechnology transfer cooperation for recombinant antibody design and production. Multiple joint projects including IgG subclasses adaptation, expression/purification/refolding of human proteins, and antibody therapy development for Parkinson's disease.
• Georg-August-University Goettingen - University MedicinecoreStrategic or Co-development PartnerCollaboration with Clinic for Psychiatry and Psychotherapy (Prof. Dr. Dr. Jens Wiltfang) on automated beta-amyloid blood test development for early diagnostics of Alzheimer dementia (Abeta-IP project).
• Imk Health Intelligence GmbHminorStrategic or Co-development PartnerJoint development of multidiagnostic platform combining enrichment methods with biomarker detection for Alzheimer's disease.
• Paul-Flechsig-Institute LeipzigcoreStrategic or Co-development PartnerLong-standing research collaboration on multiparametric test development for neurodegenerative diseases and blood screening tests for Alzheimer's disease.
• WIR! sind DIANA consortiumcoreStrategic or Co-development PartnerPart of consortium including Fraunhofer IWU Chemnitz, Technical University Chemnitz, and SensLab Leipzig for microfluidic chip based POCT analysis of Alzheimer's dementia (BioSim project).
• Hochschule für Technik und Wirtschaft DresdenminorStrategic or Co-development PartnerJoint project partner for biocompatible and sustainable POC diagnostics development.
• Otto Injection Molding GmbH & Co. KminorStrategic or Co-development PartnerPartner in sustainable POC diagnostics project for lateral flow test development.
• Bergi-Plast GmbHminorStrategic or Co-development PartnerPartner in sustainable materials project for medical diagnostics using hepatitis D point-of-care rapid test as example.
• Leipzig Medical Biobank (LIFE) of Leipzig UniversityminorStrategic or Co-development PartnerResearch collaboration for blood screening test development for Alzheimer's disease, utilizing biobank samples.
• rPeptideminorChannel Partner/ Reseller/ DistributorDistribution partner providing high quality peptides, reagents, proteins, and antibodies for Alzheimer's and Parkinson's disease research, sold through Roboscreen portfolio.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cepheid (Danaher): Cepheid is a direct peer in molecular diagnostics with the GeneXpert system and Xpert HBV/HCV viral load tests, plus a menu of CE-IVD infectious disease assays. Both companies develop PCR-based IVD kits for viral pathogens sold to clinical and reference laboratories.
• QIAGEN: QIAGEN is a direct peer: it develops and sells molecular diagnostic PCR kits (artus, QIAstat) for HBV, HCV, and other viral pathogens, plus nucleic acid extraction reagents. Roboscreen competes head-to-head in viral load quantification and shares QIAGEN-style Rotor-Gene instrument validation, making product overlap substantial.
• Hologic: Hologic is a direct peer in molecular diagnostics through its Panther system, offering CE-IVD/FDA-cleared virology assays (HBV, HCV, HIV). Both companies focus on nucleic-acid-based IVDs sold to medium- and high-throughput clinical laboratories.
• Fujirebio (H.U. Group Holdings): Fujirebio is a direct peer in neurodegenerative biomarkers, offering IVD-cleared and RUO ELISAs for tau, beta-amyloid, and alpha-synuclein. Roboscreen's hSYN, TDP43, Tau aggregate, and BetaPrion ELISAs compete in the same Alzheimer's/Parkinson's research assay market.
• Bio-Rad Laboratories: Bio-Rad is a direct peer as both a real-time PCR instrument supplier (CFX96) validated by Roboscreen and a developer of infectious disease and life science research assays. Roboscreen's kits integrate with Bio-Rad platforms and Bio-Rad's Droplet Digital PCR and ddPCR-related diagnostic assays overlap with the IVD reagent space.
• Euroimmun (PerkinElmer / Revvity): Euroimmun is a direct peer in antibody-based diagnostic and research assays, including autoimmune, infectious disease, and neurodegeneration ELISAs. Its broad neurodegenerative testing menu competes with Roboscreen's tau, synuclein, and prion ELISA portfolio.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a broad incumbent with cobas HBV/HCV quantitative PCR tests on the cobas 6800/8800 systems and Elecsys cerebrospinal fluid Alzheimer's assays. Roboscreen's hepatitis and neurodegeneration kits operate in the same clinical categories but Roche offers fully automated, integrated platforms at far greater scale.
• Abbott Molecular: Abbott Molecular is a broad incumbent in infectious disease molecular diagnostics with the Alinity m and m2000 platforms offering FDA-cleared and CE-IVD HBV/HCV viral load assays. It competes in the same hepatitis quantification space but at substantially larger scale.
• Revvity (formerly PerkinElmer Life Sciences): Revvity is a broad incumbent offering IVD reagents, newborn screening, and immunodiagnostics, with ownership of Euroimmun. Its broad diagnostics and life sciences portfolio overlaps with Roboscreen's viral pathogen and neurodegenerative reagent lines, though Revvity operates at much greater scale.

Others

• Analytik Jena (now part of Endress+Hauser): Analytik Jena is the former parent of Roboscreen (acquired it in 2005, divested via MBO in 2020) and a continued technology partner for CyBio FeliX automation and qTOWER instruments. It is adjacent rather than competing because it focuses on analytical instruments and consumables, not viral pathogen IVDs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/roboscreen-gmbh

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about roboscreen